The tree · Biology · Happens to the world · Plays out over the whole window
A treatment is approved that makes people substantially more resistant to chronic space radiation
The long shot on the biology side: rather than stopping the radiation, change the person. Some organisms shrug off doses that would kill us, and a few of the responsible genes and proteins are known. A drug or gene therapy that halves the long-term cancer and tissue damage from chronic cosmic-ray exposure would loosen the mission limits that shielding otherwise has to meet.
The test: what counts as it having happened
A drug or gene therapy is approved by a major regulator, or adopted by a space agency's crew-health standard, with evidence, to the standard that body applies, that it reduces the lifetime cancer risk, or an equivalent long-term harm measure named in the approval, from chronic galactic-cosmic-ray-type exposure by half or more.
Settled by: The regulator's approval record or the agency's published crew-health standard
The odds, by how long I live
| baselineto 2071 ± 8 | moderateto 2080 | strongto 2095 | radicalto 2136 | openno deadline |
|---|---|---|---|---|
| 8% | 10% | 15% | 35% | 45% |
Each column is a different guess at how long I live, from current trends (baseline) to open-ended. The number is the chance this happens before that deadline, assuming everything it depends on happens first. As of September 8th, 2026.
Why these numbers: A preventive therapy for a rare exposure faces an approval bar no current evidence meets, and the biology of chronic heavy-ion harm is not understood; a long shot that only becomes plausible over a century.
What this one is worth
Nothing. The headline number does not rest on this step at any remove, so however it turns out, the chance that I live and work off Earth does not change. That is not a judgement that it does not matter. It is what the tree says: this step feeds a tier above the one the headline asks about, or sits beside the equation rather than in it.
What the ledger says about this step
- Forty-one steps had their criteria tightened so that two readers would agree when each has happened, with no number moved for that alone 2026-09-20 The tree itself changed
How it could happen, and where physics would have to give way
Long shots stay in the tree on purpose, because they make the goal vivid. The rule is that each one has to be written plausibly all the way to the edge of the impossible, naming how it would work and exactly where it would break.
The mechanism: Radioprotective drugs already exist for acute exposure (amifostine protects tissue during radiotherapy). Proteins from radiation-tolerant organisms, such as the tardigrade's Dsup, have reduced DNA damage in human cells in the lab, and gene therapies that deliver a single protein are now routine medicine. The step is from lab cells to a therapy shown to cut lifetime cancer risk from chronic heavy-ion exposure, tested first in animals on the station or the Moon.
The breaking point: Nobody knows whether the harm from years of heavy-ion exposure comes mostly from DNA damage, which such proteins address, or from other tissue and vascular effects that they do not. There is no human data on chronic heavy-ion exposure at all, and a preventive therapy given to healthy people for a rare exposure faces an approval bar that no current evidence could meet.
The last 3 checks
Once a week the tree is read against the news, node by node, against the test above. Open a line to see what that week held. Every check ever made on this node is on the Radar page.
-
2026-11-01 Nothing new
No regulator approval or agency adoption of a radiation-resistance treatment. Only preclinical work (antagomirs, gene silencing, CDDO) and funding calls appeared.
-
2026-10-04 Nothing new
No regulator approval or agency standard adoption of a treatment halving chronic space radiation risk appeared. Only research and countermeasure development was found.
-
2026-09-19 Nothing new
No regulator approval or agency crew-health-standard adoption of a chronic-radiation-resistance treatment was found; radioprotectors for chronic low-dose cosmic-ray exposure remain in early research.
Revisions
| Date | Field | From | To | Why |
|---|---|---|---|---|
| 2026-09-19 | resolution | reduces the long-term harm by half or more, outcome unnamed | reduces the lifetime cancer risk, or an equivalent long-term harm measure named in the approval, by half or more; the evidence standard stays with the approving body | Step 27 outside-model review, item 50 (docs/reviews/2026-09-19-rulings.md): the outcome behind the fifty percent claim was undefined; the evidence standard is rightly delegated to the regulator or agency for a long shot. Decided September 19th, 2026. |
Think this estimate is wrong?
Here's how to tell me, and
what happens next.
The record itself is data/B-biology.toml in the public repository.